Abstract
The complex genetic landscape in ALS presents a significant challenge. Despite the increasing number of pathogenic/risk mutations reported in ALS, the true proportion of cases that can be attributed to genetic factors remains unclear, and the actual role of genome-wide screening in clinical practice is still undetermined. Here we provide a comprehensive analysis of the spectrum of genetic risk in ALS patients and assess the clinical utility of performing whole-genome sequencing (WGS).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
